Skip to main content

A Phase 2, Open-label, Multicenter Study of the Safety and Efficacy of TAK-007 in Adult Patients With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma

Clinical Trial Grant
Duke Scholars

Administered By

Duke Cancer Institute

Awarded By

Takeda Development Center Americas, Inc

Start Date

August 24, 2022

End Date

August 14, 2027
 

Administered By

Duke Cancer Institute

Awarded By

Takeda Development Center Americas, Inc

Start Date

August 24, 2022

End Date

August 14, 2027